Aurobindo Pharma的净利润在美国和欧洲需求强劲的驱动下,在问题2 FY26中上升了3.8%。 Aurobindo Pharma's net profit rose 3.8% in Q2 FY26, driven by strong U.S. and European demand.

Aurobindo Pharma报告说,由于美国和欧洲需求强劲,合并净利润增长了3.8%,达到Q2 FY26 848 克郎,收入增长了6.3%,达到 $8 286 克郎。 Aurobindo Pharma reported a 3.8% rise in consolidated net profit to ₹848 crore for Q2 FY26, with revenue up 6.3% to ₹8,286 crore, driven by strong demand in the U.S. and Europe. 配方收入同比增长10.3%,API收入下降了16.9%。 Formulations revenue grew 10.3% year-on-year, while API revenue declined 16.9%. 该公司对遵守年度指导仍然有信心。 The company remains confident in meeting annual guidance. 与此同时,印度的API市场在2025年达到142亿美元,预计到2030年将增长到214.6亿美元,劳鲁斯实验室和Zydus生命科学公司通过投资和政府奖励在全球扩展。 Meanwhile, India’s API market hit $14.2 billion in 2025 and is expected to grow to $21.46 billion by 2030, with Laurus Labs and Zydus Lifesciences expanding globally through investments and government incentives. Aurobindo的库存根据技术指标被评级为BUY,如果抗药性被打破,目标值为1,270先令。 Aurobindo’s stock is rated BUY based on technical indicators, with a target of ₹1,270 if resistance is broken.